• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Past drug failures vital to drug development process

Report: Past drug failures vital to drug development process

October 8, 2014
CenterWatch Staff

A number of investigational cancer medicines that did not succeed in clinical trials, so-called "failures," are a critical part of the drug development process, according to a report by the Wash. D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA).

The report, Researching Cancer Medicines: Setbacks and Stepping Stones, illustrates the immense challenges in bringing new medicines to patients with cancer, and explores the factors that contributed to both the approvals of new treatments and those that "failed" between 1998 and 2014. The report focuses on three cancers particularly difficult to treat: melanoma, lung cancer and brain cancer.

Key findings include:

  • 96 potential treatments for melanoma did not make it through clinical trials, but paved the way for seven approved medicines, a nearly 14:1 ratio of "failures" to "successes"
  • 10 medicines have been approved to treat lung cancer, whereas 167 other potential treatments did not make it through clinical trials
  • Only three new medicines have been approved to treat brain cancer, while another 75 investigational medicines were unsuccessful in the development process.

Despite these challenges, America's biopharmaceutical companies continue to invest in research to develop new treatments. According to the PhRMA report, there are 771 cancer medicines and vaccines either in clinical trials or awaiting review by the FDA. Of these medicines, more than 50 are for the treatment of melanoma, 98 for lung cancer and 47 for brain cancer.

"While it may sound counterintuitive, research setbacks are instrumental to furthering efforts to better understand a disease and how to treat it. They also are an indication of the incredible difficulty in developing medicines to treat cancer," said John J. Castellani, PhRMA president and CEO. "These setbacks serve as a reminder that to make progress, we need a public policy framework that supports drug development in combination with promising science so that we can bring important innovations to patients."

Significant advancements in the treatment of diseases like cancer typically are the result of cumulative innovation over time, rather than a single breakthrough in treatment. Every success—and every "failure"—builds on previous advances to improve patients' lives. Research has shown that cancer actually is a set of more than 200 extremely complex diseases and discovering medicines that effectively treat each one is a difficult task.

"While it is incredibly disappointing to see a promising new drug candidate eliminated from the pipeline, researchers take immeasurable learnings from every setback and build upon each one to develop effective therapies for patients," said Castellani.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing